Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Mirzaei, Khadijeh ^a   Hossein Nezhad, Arash ^b,c   Keshavarz, Seyed Ali ^a   Koohdani, Fariba ^a   Saboor Yaraghi, Ali Akbar ^a   Hosseini, Saeed ^a   Eshraghian, Mohammad Reza ^b   Djalali, Mahmoud ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adipokines; Circulating PPAR ; Metabolic syndrome; Obesity

Indexed keywords

ADIPOCYTOKINE; NESFATIN 1; OMENTIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGRANULIN; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG; VASPIN;

ARTICLE; BLOOD LEVEL; BODY COMPOSITION; BODY MASS; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLIC SYNDROME X; MOLECULAR INTERACTION; OBESITY; PRIORITY JOURNAL;

EID: 84890001141     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-79     Document Type: Article

References (51)

1. Metabolic syndrome, obesity, and mortality: impact of cardiorespiratory fitness. Katzmarzyk PT, Church TS, Janssen I, Ross R, Blair SN, Diabetes Care 2005 28 391 397 (Pubitemid 40170945)
2. Vaspin: a novel serpin with insulin-sensitizing effects. Wada J, Expert Opin Investig Drugs 2008 17 327 333 (Pubitemid 351578185)
3. Prevalence of metabolic syndrome in a cohort of Chinese schoolchildren: comparison of two definitions and assessment of adipokines as components by factor analysis. Wang Q, Yin J, Xu L, Cheng H, Zhao X, Xiang H, Lam HS, Mi J, Li M, BMC Public Health 2013 13 1471 2458
4. Adipose tissue as an endocrine organ. Kershaw EE, Flier JS, J Clin Endocrinol Metab 2004 89 2548 2556 (Pubitemid 38766330)
5. Role of NUBC2/nesfatin-1 in glucose control: diverse functions in islets adipocytes and brain. Nakata M, Yada T, Curr Pharm Des 2013 25 25
6. Metabolic syndrome, circulating RBP4, testosterone, and SHBG predict weight regain at 6 months after weight loss in men. Wang P, Menheere PP, Astrup A, Andersen MR, Baak MA, Larsen TM, Jebb S, Kafatos A, Pfeiffer AF, Martinez JA, et al. Obesity 2013 14 20311
7. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA, J Clin Endocrinol Metab 2013 98 2012 3673
8. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, Jang HC, Kim MS, Clin Endocrinol 2011 75 628 635
9. Serum levels of the adipokine progranulin depend on renal function. Richter J, Focke D, Ebert T, Kovacs P, Bachmann A, Lossner U, Kralisch S, Kratzsch J, Beige J, Anders M, et al. Diabetes Care 2013 36 410 414
10. Adipose tissue and adipokines-energy regulation from the human perspective. Trayhurn P, Bing C, Wood IS, J Nutr 2006 136 1935S 1939S (Pubitemid 43973602)
11. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults, Jama 2001 285 2486 2497
12. Relationship between adipocyte size and adipokine expression and secretion. Skurk T, Alberti-Huber C, Herder C, Hauner H, J Clin Endocrinol Metab 2007 92 1023 1033 (Pubitemid 46465679)
13. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM, Mol Cell 1999 4 611 617 (Pubitemid 29531140)
14. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, et al. J Clin Invest 1998 101 1354 1361 (Pubitemid 28145252)
15. Regulation of differentiation and hypertrophy of adipocytes and adipokine network by PPARgamma. Waki H, Yamauchi T, Kadowaki T, Nihon Rinsho 2010 68 210 216
16. Genetic contributions to type 2 diabetes: recent insights. Sale MM, Rich SS, Expert Rev Mol Diagn 2007 7 207 217 (Pubitemid 46513446)
17. Partial agonists activate PPARgamma using a helix 12 independent mechanism. Bruning JB, Chalmers MJ, Prasad S, Busby SA, Kamenecka TM, He Y, Nettles KW, Griffin PR, Structure 2007 15 1258 1271 (Pubitemid 47539157)
18. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model. Sharabi Y, Oron-Herman M, Kamari Y, Avni I, Peleg E, Shabtay Z, Grossman E, Shamiss A, Am J Hypertens 2007 20 206 210 (Pubitemid 46150024)
19. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Ricote M, Li A, Willson T, Kelly C, Glass C, Nature 1998 391 79 82 (Pubitemid 28079218)
20. Proinflammatory stimulation and pioglitazone treatment regulate PPARγ levels in PBMCs from healthy controls and multiple sclerosis patients. Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, Heneka T, J Immunol 2005 175 4948 4955 (Pubitemid 41456376)
21. PPARgamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome. Macias-Gonzalez M, Cardona F, Queipo-Ortuño M, Bernal R, Martin M, Tinahones F, J Nutr Biochem 2008 138 903 907 (Pubitemid 351571590)
22. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. Yang XY, Wang LH, Chen T, Hodge DR, Resau JH, DaSilva L, Farrar WL, J Biol Chem 2000 275 4541 4544 (Pubitemid 30108833)
23. PPARgamma in monocytes: less pain, any gain? Spiegelman BM, Cell 1998 93 153 155
24. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. Rosen ED, Spiegelman BM, J Biol Chem 2001 276 37731 37734
25. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. McIntyre TM, Pontsler AV, Silva AR, St Hilaire A, Xu Y, Hinshaw JC, Zimmerman GA, Hama K, Aoki J, Arai H, Prestwich GD, Proc Natl Acad Sci USA 2003 100 131 136 (Pubitemid 36078041)
26. Association between PPAR-gamma and RXR-alpha gene polymorphism and metabolic syndrome risk: a case-control study of a Chinese Han population. Shi H, Yu X, Li Q, Ye X, Gao Y, Ma J, Cheng J, Lu Y, Du W, Du J, et al. Arch Med Res 2012 43 233 242
27. The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the quebec family study. Robitaille J, Despres JP, Perusse L, Vohl MC, Clin Genet 2003 63 109 116 (Pubitemid 36949904)
28. The Pro12Ala polymorphism of the PPAR gamma 2 gene influences sex hormone-binding globulin level and its relationship to the development of the metabolic syndrome in young Finnish men. Mousavinasab F, Tahtinen T, Jokelainen J, Koskela P, Vanhala M, Oikarinen J, Laakso M, Keinanen-Kiukaanniemi S, Endocrine 2006 30 185 190 (Pubitemid 46340519)
29. Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R, Diabetologia 1985 28 412 419
30. Evidence of a role of ANGPTL6 in resting metabolic rate and its potential application in treatment of obesity. Mirzaei K, Hossein-Nezhad A, Chamari M, Shahbazi S, Minerva Endocrinol 2011 36 13 21
31. Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Miles PD, Barak Y, Evans RM, Olefsky JM, Am J Physiol Endocrinol Metab 2003 284 618 626
32. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, et al. Mol Cell 1999 4 597 609 (Pubitemid 29531139)
33. PPAR gamma agonist and antagonist. Kadowaki T, Nihon Yakurigaku Zasshi 2001 118 321 326
34. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. Miles PD, Barak Y, He W, Evans RM, Olefsky JM, J Clin Invest 2000 105 287 292 (Pubitemid 30094448)
35. Obesity, insulin resistance, and the metabolic syndrome: determinants of endothelial dysfunction in whites and blacks. Lteif AA, Han K, Mather KJ, Circulation 2005 112 32 38 (Pubitemid 40962566)
36. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, Haghazali M, Asgari F, Nutr Metab 2010 7 1743 7075
37. Use and abuse of HOMA modeling. Wallace TM, Levy JC, Matthews DR, Diabetes Care 2004 27 1487 1495 (Pubitemid 38680001)
38. Comparative evaluation of simple indices of insulin resistance. Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, Hermansen K, Tapsell L, Riccardi G, Metabolism 2004 53 1522 1526 (Pubitemid 39556363)
39. Glucose intolerance and aging: evidence for tissue insensitivity to insulin. Defronzo RA, Diabetes 1979 28 1095 1101 (Pubitemid 10215014)
40. Insulin Resistance and Impaired Mitochondrial Function in Obese Adolescent Girls. Slattery MJ, Bredella MA, Thakur H, Torriani M, Misra M, Metab Syndr Relat Disord 2013 19 19
41. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Reaven GM, Hollenbeck CB, Chen YD, Diabetologia 1989 32 52 55 (Pubitemid 19061742)
42. The many faces of PPARγ Lehrke M, Lazar M, Cell 2005 123 993 999
43. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Straus D, Pascual G, Li M, Welch J, Ricote M, Hsiang C, Sengchanthalangsy L, Proc Natl Acad Sci USA 2000 97 4844 4849 (Pubitemid 30238645)
44. The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation? Saldanha JF, Carrero JJ, Lobo JC, Stockler-Pinto MB, Leal VO, Calixto A, Geloneze B, Mafra D, Regul Pept 2012 173 82 85
45. Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet beta- and MIN6 cells. Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S, J Endocrinol 2011 208 9 R16
46. Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Yamada M, Horiguchi K, Umezawa R, Hashimoto K, Satoh T, Ozawa A, Shibusawa N, Monden T, Okada S, Shimizu H, Mori M, Endocrinology 2010 151 2494 2503
47. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, Franco OH, Wang J, Li H, Liu Y, Lin X, J Clin Endocrinol Metab 2007 92 4827 4834 (Pubitemid 350223466)
48. Peroxisome proliferator-activated receptors-alpha and -gamma, and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue. Rosell M, Hondares E, Iwamoto S, Gonzalez FJ, Wabitsch M, Staels B, Olmos Y, Monsalve M, Giralt M, Iglesias R, Villarroya F, Endocrinology 2012 153 1162 1173
49. Omentin plasma levels and gene expression are decreased in obesity. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, et al. Diabetes 2007 56 1655 1661 (Pubitemid 46842600)
50. Comparative effects of metformin and pioglitazone on omentin and leptin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M, Regul Pept 2013 182 1 6
51. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Bluher M, Endocrine 2012 41 176 182